In affluent areas with a high per-capita GDP, radium-223 therapy may be cost effective. Uncertainty analyses revealed that the model is robust to all the input parameters.Ĭonclusion: Radium-223 is unlikely to be cost effective in patients with bone mCRPC at the current WTP threshold, from a Chinese health system perspective. The probability of Ra-223 being cost effective for the patients with bone mCRPC was sharply low (<0.5%) at a willingness-to-pay threshold of $38,136/QALY. Results: Compared with the BSC arm, radium-223 achieved an excess 0.344 QALYs with an incremental cost of $29,459, resulting in an ICUR of $85,647 per QALY. Uncertainty analyses were performed to assess the robustness of our conclusions. The base-case model results were quality-adjusted life year (QALY), total cost, and incremental cost-utility ratio (ICUR). Utility values were derived from the published literature. Costs were collected from a Chinese health system perspective. The patients and interventions were modeled according to the ALSYMPCA trial.
RADIUM PROSTATE CANCER PLUS
Materials and methods: A Markov model was developed to estimate the long-term health and economic outcomes of radium-223 plus best standard care (BSC) treatment and BSC only for bone mCRPC patients over a lifetime horizon. Objective: To assess the cost effectiveness of radium-223 dichloride for patients with metastatic castration-resistant prostate cancer (mCRPC) in China. 2Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China.1Department of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, China.Xiaohui Zeng 1 †, Qiao Liu 2 †, Chongqing Tan 2, Xiaomin Wan 2, Yunhua Wang 1* and Xiaowei Ma 1*
0 kommentar(er)
